Recent developments in the design of bioreductive drugs

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Denny, W A ^a   Wilson, W R ^a   Hay, M P ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

ADEPT; GDEPT; Hypoxia; Radiation activated cytotoxin

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; CHLORMETHINE; DNA TOPOISOMERASE; MISONIDAZOLE; MITOMYCIN C; PRODRUG; QUINONE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING);

CELL KILLING; CONFERENCE PAPER; CYTOTOXICITY; DRUG ACTIVATION; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; IONIZING RADIATION; PH; PRIORITY JOURNAL; ANIMAL; BIOTRANSFORMATION; DRUG ANTAGONISM; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; REVIEW; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DNA TOPOISOMERASES, TYPE II; DRUG DESIGN; HUMANS; OXIDATION-REDUCTION; PRODRUGS;

EID: 0029884764     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. ADAMS GE AND STRATFORD IJ. (1994). Bioreductive drugs for cancer therapy: the search for tumor specificity. Int. J. Radiat. Oncol. Biol. Phys., 29, 231-238.
2. ALLEY SC AND HOPKINS PB. (1994). DNA-DNA interstrand cross-linking by 2,5-bis(1-aziridinyl)-3,6-bis(carbethoxyamino)-1,4-benzoquinone : covalent structure of the dG-to-dG cross-links in calf thymus DNA and a synthetic DNA duplex. Chem. Res. Toxicol., 7, 666-672.
3. ANDERSON RF, DENNY WA, WARE DC AND WILSON WR. (1996). Pulse radiolysis studies on the mechanism of hypoxia-selective cytotoxicity of a cobalt-mustard complex. Br. J. Cancer 74 (Suppl. 27) S48-S51.
4. ATWELL GJ, SYKES BM, O'CONNOR CJ AND DENNY WA. (1994). Relationships between structure and kinetics of cyclization of 2-aminoaryl amides - potential prodrugs of cyclization-activated aromatic mustards. J. Med. Chem., 37, 371-380.
5. BAGSHAWE KD. (1995). Antibody-directed enzyme prodrug therapy: a review. Drug Devel. Res., 34, 220-230.
6. BATCHELDER RM, WILSON WR, HAY MP AND DENNY WA. (1996). Oxygen dependence of the cytotoxicity of the enediyne antitumor antibiotic esperamicin A1. Br. J. Cancer 74 (Suppl. 27) S52-S56.
7. BAYS JP, BLUMER ST, BARAL-TOSH S, BEHAR D AND NETA P. (1983). Intramolecular electron transfer and dehalogenation of nitroaromatic anion radicals. J. Am. Chem. Soc., 105, 320-324.
8. BROWN JM. (1993). SR-4233 (tirapazamine) - a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163-1170.
9. COWAN DSM, HICKS KO AND WILSON WR. (1996). Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br. J. Cancer 74 (Suppl. 27) S28-S31.
10. DENNIS MF, STRATFORD MRL, WARDMAN P AND WATTS ME. (1985). Cellular uptake of misonidazole and analogues with acidic or basic functions. Int. J. Radiat. Biol., 47, 629-643.
11. DENNY WA AND WILSON WR. (1986). Consideration for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem., 29, 879-887.
12. DENNY WA AND WILSON WR. (1993). Bioreducible mustards - a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metast. Rev., 12, 135-151.
13. DENNY WA, ROBERTS PB, ANDERSON RF, BROWN JM AND WILSON WR. (1992a). NLA-1 - a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int. J. Radiat. Oncol. Biol. Phys., 22, 553-556.
14. DENNY WA, ATWELL GJ, ROBERTS PB, ANDERSON RF, BOYD M, LOCK CJL AND WILSON WR. (1992b). Hypoxia-selective antitumor agents. 6. 4-(alkylamino)nitroquinolines - a new class of hypoxia-selective cytotoxins. J. Med. Chem., 35, 4832-4841.
15. DENNY WA, WILSON WR, TERCEL M, VAN ZIJL P AND PULLEN SM. (1994). Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction. Int. J. Radiat. Oncol. Biol. Phys., 29, 317-321.
16. DE VOSS JD AND TOWNSEND CA. (1990). Site-specific atom transfer to calichemicin. J. Am. Chem. Soc., 112, 9669-9670.
17. FIRESTONE A, MULCAHY RT AND BORCH RF. (1991). Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. J. Med. Chem., 34, 2933-2935.
18. GOLIK J, DUBAY G, GROENWALD G, KAWAGUCHI H, KONISHI M, KRISHNAN B, OJIKUMA H, SAITOH K AND DOYLE TW. (1987). Esperamicins, a novel class of potent antitumor antibiotics. 3. Structures of esperamicins A1, A2 and A1b. J. Am. Chem. Soc., 109, 3462-3464.
19. GOURDIE T, VALU KK, GRAVATT GL, BORITZKI TJ, BAGULEY BC, WILSON WR, WOODGATE PD AND DENNY WA. (1990). DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. J. Med. Chem., 33, 1177-1186.
20. HAY MP, WILSON WR AND DENNY WA. (1995). A novel enediyne prodrug as a substrate for antibody enzyme prodrug therapy (ADEPT), using E. coli B nitroreductase. Bioorganic & Medicinal Chem. Lett., 5, 2829-2834.
21. HAY MP, DENNY WA AND WILSON WR. (1996). Nitroimidazole-based 'extruded mustards' designed as reductively-activated hypoxia-selective cytotoxins. Anti - Cancer Drug Design (in press).
22. KIRKPATRICK DL, JOHNSON KE AND SARTORELLI A. (1986). Nitrobenzyl derivatives as bioreductive alkylating agents; evidence for the reductive formation of a reactive intermediate. J. Med. Chem., 29, 2048-2052.
23. KNOX RJ, FRIEDLOS F AND BOLAND MP. (1993). The bioactivation of CB-1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metast. Rev., 12, 195-212.
24. LEE M, RHODES AL, WYATT MD, D'INCALCI M, FORROW S AND HARTLEY AJ. (1993). In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. J. Med. Chem., 36, 863-870.
25. LI LH, DEKONING TF, KELLY RC, KRUEGER WC, MCGOVERN JP, PADBURY GE, PETZOLD GL, WALLACE TL, OUDING RJ, PRAIRIE MD AND GEBHARD I. (1992). Cytotoxicity and antitumor activity of carzelesin, a potent prodrug cyclopropylpyrroloindole analogue. Cancer Res., 52, 4904-4913.
26. MCKEOWN SR, HEJMADI MV, MCINTYRE IA, MCALEER JJAA AND PATTERSON LH. (1995). AQ4N; an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br. J. Cancer, 72, 76-81.
27. MAUGER AB, BURKE PJ, SOMANI HH, FRIEDLOS P AND KNOX RJ. (1994). Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem., 37, 3452-3458.
28. MONGE A, PALOP JA, DECERAIN AL, SENADOR V, MARTINEZ-CRESPO FJ, SAINZ Y, NARRO S, GARCIA E, DEMIGUEL C, GONZALEZ M, HAMILTON E, BARKER AJ, CLARKE ED AND GREENHOW DT. (1995). Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med. Chem., 38, 1786-1792.
29. MOODY CJ, O'SULLIVAN M, STRATFORD IJ, STEPHENS MA, WORKMAN P, BAILEY SM AND LEWIS A. (1994). Cyclopropamitosenes: novel bioreductive anticancer agents - mechanism of action and enzymic reduction. Anti-Cancer Drugs, 5, 367-372.
30. NAYLOR MA, ADAMS GE, HAIGH A, COLE S, JENNER T, ROBERTSON N, SIEMANN D, STEPHENS MA AND STRATFORD IJ. (1995). Fused pyrazine mono-N-oxides as bioreductive drugs. 3. Characterization of RB 90740 in vitro and in vivo. Anti - Cancer Drugs, 6, 259-269.
31. NICOLAOU KC, DAI WM, TSAY SC, ESTEVEZ VA AND WRASIDLO W. (1992). Designed enediynes - a new class of DNA-cleaving molecules with potent and selective anticancer activity. Science, 256, 1172-1178.
32. NISHIMOTO S, HATTA H, UESHIMA H AND KAGIYA T. (1992). 1-(5′-Fluoro-6′hydroxy-5′,6′-dihydrouracil-5′-yl)- 5-fluorouracil, a novel N(1)-C(9)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J. Med. Chem., 35, 2711-2712.
33. PALMER BD, WILSON WR, PULLEN SM AND DENNY WA. (1990). Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J. Med. Chem., 33, 112-121.
34. PALMER BD, WILSON WR, CLIFFE S AND DENNY WA. (1992). Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J. Med. Chem., 35, 3214-3222.
35. PALMER BD, VAN ZIJL P, DENNY WA AND WILSON WR. (1995). Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem., 38, 1229-1241.
36. PAPADOPOULOU MV, EPPERLY MW, SHIELDS DS AND BLOOMER WD. (1992). Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds. Jpn. J. Cancer Res., 83, 410-414.
37. PATTERSON LH, CRAVEN MR, FISHER GR AND TEESDALE-SPITTLE P. (1994). Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Biochem. Pharmacol. Oncol. Res., 6, 533-538.
38. ROSS D, SIEGEL D, BEALL H, PRAKASH AS, MULCAHY RT AND GIBSON NW. (1993). DT-diaphorase in activation and detoxification of quinones bioreductive activation of mitomycin-C. Cancer Metast. Rev., 12, 83-101.
39. SARTORELLI AC. (1988). Therapeutic attack of hypoxic cells of solid tumours: Presidential address. Cancer Res., 48, 775-778.
40. SCHULZ WG, ISLAM I AND SKIBO EB. (1995). Pyrrolo[1,2-a]benzimidazole-based quinones and iminoquinones. The role of the 3-substituent on cytotoxicity. J. Med. Chem., 38, 109-118.
41. SIIM BG, DENNY WA AND WILSON WR. (1994). Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? Int. J. Radiat. Oncol. Biol. Phys., 29, 311-315.
42. SKIBO EB, ISLAM I, HEILEMAN MJ AND SCHULZ WG. (1994). Structure activity studies of benzimidazole-based DNA-cleaving agents comparison of benzimidazole, pyrrolobenzimidazole, and tetrahydropyridobenzimidazole analogues. J. Med. Chem., 37, 78-92.
43. SMITSKAMP-WILMS E, PETERS GJ, PINEDO HM, VANARCOTTE J AND GIACCONE G. (1994). Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem. Pharmacol., 47, 1325-1332.
44. SYKES BM, ATWELL GJ, DENNY WA AND O'CONNOR CJ. (1995). Radiolytic studies of the reductive cyclization of nitroaryl amides: cyclization via hydroxylamine intermediates. J. Phys. Org. Chem., 8, 587-596.
45. VERWEIJ J, AAMDAL S, SCHELLENS J, KOIER I AND LUND B. (1994). Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. Oncol. Res., 6, 519-523.
46. WARE DC, PALMER BD, WILSON WR AND DENNY WA. (1993). Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins - synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J. Med. Chem., 36, 1839-1846.
47. WILSON WR AND DENNY WA. (1992). DNA binding nitroheterocycles as hypoxia-selective cytotoxins. In Radiation Research: a Twentieth Century Perspective. Dewey WC, Eddington M, Fry RJM, Hall EJ and Whitmore GF. (eds), p 796: Academic Press: New York.
48. WILSON WR, DENNY WA AND TERCEL M. (1995) Radiation-activated cytotoxins: a new use for Roentgen's rays in cancer treatment. Proc. 10th Int. Congr. Radiat. Res. (in press).
49. WILSON WR, DENNY WA, PULLEN SM, THOMPSON KM, LI AE, PATTERSON LH AND LEE HH. (1996a). Tertiary amine oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br. J. Cancer 70 (Suppl. 27) S43-S47.
50. WILSON WR, FERRY DM, WARE DC, DENNY WA, ANDERSON RF AND ROBERTS BD. (1996b). Activation of the cobalt(III) complex SN 24771 by ionising radiation; a new strategy for killing hypoxic tumour cells. (manuscript in preparation).
51. WILSON WR, PALMER BD, PULLEN SM, MOSELEN JW, XING ZX AND DENNY WA. (1996c). NSC 654891, a new dinitrobenzamide mustard designed to combine selectivity for both hypoxia and acidosis in tumours. Anti-Cancer Drug Design (submitted).
52. WORKMAN P AND STRATFORD IJ. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast. Rev., 12, 73-82.